Top Medical Device Companies in 2026: Revenue Rankings, Market Share, and Industry Trends
A comprehensive guide to the world's largest medical device companies ranked by revenue — including Medtronic, Johnson & Johnson, Abbott, Siemens Healthineers, and more — with 2026 market data, strategic shifts, and what's driving growth.
The Global Medical Device Market at a Glance
The global medical device industry reached an estimated $586 billion in 2025 and is projected to hit $623 billion in 2026, growing at a compound annual growth rate (CAGR) of 5.5% to 6.9% depending on the methodology used. By 2030, the market is expected to approach $955 billion, and long-range forecasts put the industry at over $1 trillion by 2034 (Fortune Business Insights; BusinessStats Research Desk; Towards Healthcare).
The top 100 medtech companies collectively generated $486.7 billion in revenue and employ approximately 1.21 million workers worldwide (BusinessStats). North America commands roughly 40% of the global market — driven by the presence of giants like Medtronic, Johnson & Johnson, and Abbott — while Asia-Pacific is the fastest-growing region, fueled by expanding healthcare infrastructure and government investment in China, India, Japan, and South Korea (Coherent Market Insights).
In 2025, the FDA authorized a record 258 AI/ML-enabled medical devices, bringing the cumulative total to over 1,300 — a clear signal that artificial intelligence is no longer experimental in medtech; it is mainstream (BusinessStats; FDA).
Top 10 Medical Device Companies by Revenue (2025 Rankings)
The following rankings are drawn from the Medtech Big 100 report published by Medical Design & Outsourcing and MassDevice, which ranks companies by annual medical device revenue. Where companies operate across multiple sectors (pharmaceuticals, consumer health, etc.), only the medical device segment revenue is counted.
| Rank | Company | Medical Device Revenue | HQ | Primary Focus |
|---|---|---|---|---|
| 1 | Medtronic | $33.5B | Ireland / US | Cardiovascular, neuroscience, surgical, diabetes |
| 2 | Johnson & Johnson MedTech | $31.9B | US | Orthopedics, surgery, cardiovascular, vision |
| 3 | Medline Industries | $25.5B | US | Medical supplies, distribution |
| 4 | Siemens Healthineers | $24.2B | Germany | Diagnostic imaging, laboratory diagnostics |
| 5 | Stryker | $22.6B | US | Orthopedics, neurotechnology, MedSurg |
| 6 | GE HealthCare | $19.7B | US | Imaging, patient care, pharmaceutical diagnostics |
| 7 | Royal Philips | $19.5B | Netherlands | Imaging, patient monitoring, personal health |
| 8 | Abbott (device segment) | $19.0B | US | Cardiovascular, diagnostics, diabetes care |
| 9 | Boston Scientific | $16.7B | US | Interventional cardiology, endoscopy, neuromodulation |
| 10 | BD (medical segments) | $15.1B | US | Medication delivery, diagnostics, biosciences |
Sources: MassDevice Medtech Big 100 (2025 edition); Medical Design & Outsourcing; company annual reports.
The Top 5 Companies in Depth
1. Medtronic — $33.5 Billion
Medtronic remains the world's largest pure-play medical device company, operating across four business units: cardiovascular ($11.8B), neuroscience ($9.4B), medical-surgical, and diabetes. The company employs approximately 95,000 people across more than 140 countries.
Key 2026 developments:
MiniMed separation: Medtronic is spinning off its diabetes business (annual revenue of $2.8B) into an independent publicly traded company called MiniMed. The IPO launched in February 2026 at a valuation of approximately $7.86 billion. Medtronic will retain roughly 90% ownership initially, with a full split-off planned. CEO Geoff Martha characterized the move as portfolio simplification: diabetes is predominantly a B2C business, while Medtronic's other franchises are B2B (MassDevice; Medtronic press releases).
Strong growth momentum: In Q3 of fiscal year 2026, Medtronic reported worldwide revenue of $9.017 billion — the highest enterprise revenue growth in 10 quarters at 8.7% reported / 6.0% organic. The cardiovascular segment led with 13.1% growth, driven by pulsed-field ablation systems (Affera, PulseSelect) for atrial fibrillation (Medtronic Q3 FY26 earnings).
Surgical robotics entry: Medtronic's Hugo robotic-assisted surgery system received FDA clearance for urologic procedures in 2025, marking the company's entry into the soft-tissue robotics market long dominated by Intuitive Surgical.
Regulatory relevance: Medtronic's breadth across therapeutic areas makes it a company that regulatory professionals encounter frequently — from 510(k) clearances for cardiac rhythm devices to PMA supplements for novel neuromodulation systems.
2. Johnson & Johnson MedTech — $31.9 Billion
J&J's MedTech segment accounts for approximately 36% of the company's total revenue and spans orthopedics (DePuy Synthes), surgery (Ethicon), cardiovascular (Biosense Webster), and vision. In 2025, the segment delivered nearly $34 billion in sales with 5.4% operational growth, supported by 15 major product launches (Zacks; Yahoo Finance).
Key 2026 developments:
DePuy Synthes separation: In October 2025, J&J announced its intent to separate the orthopedics franchise into a standalone company. By February 2026, Bloomberg reported that J&J was exploring a potential sale valued at over $20 billion. If completed, the separation would create the world's largest standalone orthopedics company — but it would also narrow J&J MedTech's portfolio, shifting focus toward higher-growth, higher-margin segments like electrophysiology and surgical robotics (J&J press release; MassDevice).
Ottava surgical robot: J&J is developing a soft-tissue surgical robot called Ottava, targeting FDA approval in 2026. If cleared, Ottava would compete directly with Intuitive Surgical's da Vinci and Medtronic's Hugo in the rapidly growing robotic surgery market (AlphaSense; IQVIA).
Potential #1 ranking: With Medtronic's diabetes separation removing approximately $2.8B in annual revenue, J&J MedTech is positioned to become the world's largest medical device company by the next Medtech Big 100 report (Medical Design & Outsourcing).
Regulatory relevance: J&J's portfolio touches virtually every regulatory pathway — from Class II 510(k) clearances for surgical instruments to PMA devices in electrophysiology. The DePuy Synthes separation will create significant regulatory restructuring as product lines, quality systems, and marketing authorizations are divided between entities.
3. Medline Industries — $25.5 Billion
Medline is the largest privately held medical device company in the world and the largest manufacturer and distributor of medical supplies in the United States. Unlike the other companies on this list, Medline does not develop implantable devices or capital equipment — its business centers on gloves, gowns, surgical trays, and supply chain logistics for hospitals and healthcare systems.
The company made headlines in 2025 with a $6.26 billion IPO, one of the largest in medtech history, underscoring how large non-device supply-chain players have become in the broader healthcare ecosystem (iData Research).
Regulatory relevance: Medline's products are primarily Class I devices, but the company plays an outsized role in healthcare supply chain compliance, sterilization standards, and distribution quality requirements under 21 CFR Part 820 / QMSR.
4. Siemens Healthineers — $24.2 Billion
Siemens Healthineers is the global leader in diagnostic imaging and laboratory diagnostics, headquartered in Erlangen, Germany. The company's revenue of approximately €22 billion (€16.54B in medical devices specifically) comes from imaging systems (CT, MRI, PET, X-ray), laboratory diagnostics, and advanced therapies.
Siemens Healthineers competes directly with GE HealthCare and Philips in the imaging space. The company has invested heavily in AI-powered imaging analysis, digital twin technology for hospital operations, and molecular diagnostics through its Varian business (radiation therapy) (iData Research; Coherent Market Insights).
Regulatory relevance: Imaging devices are subject to both electromagnetic compatibility (EMC) standards and software lifecycle requirements (IEC 62304). Siemens Healthineers is a frequent participant in FDA pre-submission meetings for AI/ML-enabled imaging features.
5. Stryker — $22.6 Billion
Stryker is a global leader in orthopedic implants, neurotechnology, and surgical equipment, with over 12,000 patents worldwide. The company's growth strategy is anchored by the MAKO robotic-assisted surgery platform, which has surpassed 3,000 installed systems and 2 million procedures globally (AlphaSense; Yahoo Finance).
Key 2026 developments:
MAKO RPS launch: In early 2026, Stryker debuted the MAKO RPS, a smaller, more affordable handheld robotic system designed to expand robotic-assisted orthopedic surgery into ambulatory surgery centers (ASCs) and smaller hospitals. Morgan Stanley survey data shows that 75% of hospital executives planning to purchase an orthopedic robot in the next 12 months intend to buy a MAKO system (AlphaSense; 24/7 Wall St).
Strong guidance: Stryker projects 8% to 9.5% organic revenue growth in 2026, with adjusted EPS of $14.90 to $15.10. MAKO system placements and rising utilization are acting as a "durable growth flywheel" (TradingView; Zacks).
ASC expansion: Stryker is actively targeting the shift to outpatient care, with products and service models adapted for ambulatory surgery centers — a trend affecting every major device manufacturer.
Regulatory relevance: Orthopedic implants face rigorous biocompatibility testing (ISO 10993), mechanical testing, and post-market surveillance requirements. Stryker's robotic systems require FDA clearance for both hardware and software components.
Companies 6–10: GE HealthCare, Philips, Abbott, Boston Scientific, BD
GE HealthCare — $19.7 Billion
Spun off from General Electric in 2023, GE HealthCare generates more than 40% of its revenue from imaging and operates across four segments: imaging, advanced visualization, patient care solutions, and pharmaceutical diagnostics. The company is benefiting from aging population demographics globally and the expansion of AI-powered diagnostic tools (Motley Fool).
Royal Philips — $19.5 Billion
Philips has undergone significant portfolio restructuring, divesting its personal health and lighting businesses to focus on health technology — specifically imaging, patient monitoring, and connected care. The company has faced challenges including a massive recall of sleep apnea devices (CPAP machines) initiated in 2021, which resulted in a consent decree from the FDA. Recovery from this recall continues to be a key narrative for the company.
Abbott Laboratories (Device Segment) — $19.0 Billion
Abbott's device segment represents approximately 78% of total company revenue and spans cardiovascular (stents, structural heart), diagnostics (including the FreeStyle Libre continuous glucose monitor), and neuromodulation. The FreeStyle Libre franchise has been a standout growth driver, competing with Dexcom in the rapidly expanding CGM market (LinkedIn/Zahiri; GetReskilled).
Boston Scientific — $16.7 Billion
Boston Scientific specializes in interventional cardiology, endoscopy, urology, and neuromodulation. The company has been an active acquirer, using tuck-in deals to expand into high-growth adjacencies. Its WATCHMAN left atrial appendage closure device and FARAPULSE pulsed-field ablation system are key growth drivers in the electrophysiology space.
BD (Medical Segments) — $15.1 Billion
Becton, Dickinson and Company (BD) is the world's largest manufacturer of syringes, needles, and IV catheters, with a growing diagnostics business. BD has announced plans to separate its diabetes care business (similar to Medtronic's MiniMed spinoff), reflecting a broader trend of portfolio simplification among large medtech conglomerates.
Notable Companies Outside the Top 10
Intuitive Surgical — The Robotics Leader
Although not a top-10 company by total revenue, Intuitive Surgical warrants special attention as the dominant force in surgical robotics. In 2025, the company reported:
- Total revenue of $10.1 billion (up 21% year-over-year)
- Over 3.1 million procedures performed using da Vinci systems
- More than 11,000 da Vinci systems installed worldwide
- Free cash flow of $2.5 billion, nearly double the prior year
The flagship da Vinci 5 system, which received FDA clearance in 2025, drove 303 of 532 system placements in Q4 alone. For 2026, Intuitive expects procedure growth of 13% to 15% and recently received FDA clearance for da Vinci 5 use in certain cardiac procedures, expanding its addressable market by approximately 160,000 procedures annually (TIKR; TradingView; Finimize).
Danaher Corporation — $9.8B (device segment)
Danaher's medical device segment (41% of total revenue) focuses on life sciences tools and diagnostics. The company is known for its Danaher Business System (DBS), a continuous improvement methodology that has been widely studied in the medtech industry.
Dexcom — CGM Disruptor
Dexcom is a pure-play continuous glucose monitoring (CGM) company with approximately 10,200 employees. At the ATTD 2026 conference, Dexcom presented data showing that its G7 system improved A1C levels and supported weight management in type 2 diabetes patients not using insulin (Xtalks).
Solventum — The 3M Spinoff
Solventum was spun off from 3M in 2024 and focuses on healthcare information systems, wound care, and filtration. As a newly independent company, it is building out its own regulatory affairs infrastructure and quality management system.
Key Industry Trends Shaping 2026
1. Surgical Robotics Is Entering a Competitive Phase
The surgical robotics market is projected to grow from $13.7 billion in 2025 to $27.1 billion by 2030 (AlphaSense). After years of Intuitive Surgical holding a near-monopoly in soft-tissue robotics, the field is becoming genuinely competitive:
- Intuitive Surgical continues to dominate with over 11,000 installed da Vinci systems
- Medtronic's Hugo received FDA clearance for urology in 2025 and is expanding
- J&J's Ottava is targeting FDA approval in 2026
- Stryker's MAKO leads orthopedic robotics with 3,000+ installed systems
For regulatory professionals, this competition means more 510(k) and De Novo submissions for robotic systems, new predicate device debates, and evolving FDA guidance on software-as-a-medical-device (SaMD) for AI-enabled robotic features.
2. AI/ML Devices Are Mainstream
The FDA authorized a record 258 AI/ML-enabled devices in 2025 alone, bringing the cumulative total past 1,300. AI is no longer confined to diagnostic imaging — it is expanding into surgical assistance, predictive analytics, drug delivery optimization, and patient monitoring. The EU AI Act, which began imposing direct obligations on high-risk AI systems (including medical devices) in 2025, adds a parallel regulatory track for companies operating in Europe (Clarkston Consulting; Deloitte).
3. Portfolio Simplification and Spinoffs
Major medtech companies are aggressively simplifying their portfolios:
- Medtronic is spinning off MiniMed (diabetes, ~$2.8B revenue)
- J&J may sell or separate DePuy Synthes (orthopedics, ~$10B+ revenue)
- BD is separating its diabetes care business
- Baxter previously spun off its kidney care business as Vantive
The pattern reflects pressure from investors to focus on higher-margin, faster-growing franchises — and creates new regulatory entities that must build standalone quality systems, obtain their own ISO 13485 certifications, and manage transferred marketing authorizations.
4. Shift to Outpatient and Ambulatory Surgery Centers
The migration of procedures from hospitals to ambulatory surgery centers (ASCs) and home settings is reshaping the market. Device companies are developing smaller, more portable systems — like Stryker's MAKO RPS — to serve ASCs. CMS's 2026 Hospital Outpatient Prospective Payment System (OPPS) and ASC final rule continues to expand the list of procedures reimbursable in ASC settings (Deloitte; Clarkston Consulting).
5. Tariff and Supply Chain Pressures
An escalating tariff environment is forcing medtech companies to accelerate reshoring and regionalization of manufacturing. BMI/Fitch Solutions projects that tariff- and procurement-driven pricing pressures will persist through 2026, accelerating moves toward domestic production in the US and EU (BMI; Clarkston Consulting). For regulatory professionals, this means more manufacturing site transfers, process revalidation, and regulatory notifications to FDA and Notified Bodies.
Regional Market Breakdown
| Region | Market Share (2026 est.) | Key Trend |
|---|---|---|
| North America | ~40% | Dominant market; strong R&D ecosystem; FDA regulatory clarity |
| Europe | ~25% | EU MDR/IVDR transition driving compliance investment |
| Asia-Pacific | ~24.5% (fastest growing) | Manufacturing expansion; rising healthcare spending |
| Rest of World | ~10.5% | Emerging market access driving new registrations |
Source: Coherent Market Insights; Statista; Towards Healthcare.
The US medical device market alone is valued at approximately $203 billion in 2026, with projected growth to $346 billion by 2035 (CAGR 6.2%) (Precedence Research via Yahoo Finance).
What This Means for Regulatory Professionals
Understanding the competitive landscape of medical device companies is not just market intelligence — it has direct regulatory implications:
If you work at or with these companies, the spinoff trend means you may be involved in transferring marketing authorizations, splitting quality systems, obtaining new ISO 13485 certifications, and negotiating regulatory asset allocation between parent and spinoff entities.
If you are a regulatory consultant, knowing which companies are expanding into new therapeutic areas (e.g., surgical robotics, AI-enabled diagnostics) helps you anticipate the types of submissions, predicate device strategies, and clinical evidence requirements you will encounter.
If you are entering the medical device market, understanding who the major players are — and which product categories they dominate — is essential for competitive positioning, predicate device searches, and regulatory pathway selection.
Looking Ahead
The medical device industry in 2026 is defined by scale, consolidation, and technological transformation. The top 25 companies control roughly 75% of the global market (LinkedIn/Zahiri), but the competitive landscape is being reshaped by AI, surgical robotics, portfolio spinoffs, and the shift toward outpatient care.
The companies that will lead in 2027 and beyond are those that combine scale with agility — investing in AI and robotics while streamlining portfolios to focus on their highest-value franchises. For regulatory professionals, staying current on these industry dynamics is essential for anticipating the submissions, inspections, and compliance challenges that lie ahead.
Data sources: MassDevice Medtech Big 100 (2025); Medical Design & Outsourcing; BusinessStats Research Desk; Fortune Business Insights; Coherent Market Insights; Towards Healthcare; Statista; company earnings reports and SEC filings. Revenue figures are based on the most recent full-year data available (primarily fiscal year 2024/2025). Market size projections vary by source and methodology.